Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC(2) melanoma multi-antigen therapeutic vaccine
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
ALVAC(2) melanoma multi-antigen therapeutic vaccine is a biological, multi-antigen therapeutic vaccine developed for the treatment of metastatic melanoma. It is based on a recombinant canarypox virus (ALVAC) vector, which is designed to deliver multiple melanoma-associated antigens, such as gp100, to the immune system. This aims to stimulate a robust immune response, specifically cytotoxic T lymphocytes (CTLs), against melanoma cells to exert a therapeutic effect.
- Other names
- ALVAC(2) multi-antigen melanoma vaccineALVAC(2)-TRICOM melanoma vaccineALVAC(2)-hB7.1/ICAM-1/LFA-3/MAGE-1,3/MART-1/gp100/NY-ESO-1
02
Targets
PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on ALVAC(2) melanoma multi-antigen therapeutic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC(2) melanoma multi-antigen therapeutic vaccine.